Point72 Hong Kong’s Heron Therapeutics HRTX Stock Holding History

Point72 Hong Kong’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,518	Closed	-$108K	–	796
2022 Q3	$108K	Buy	+25,518	New	+$99.9K	﹤0.01%	1213
2022 Q2	–	Sell	-8,355	Closed	-$48K	–	2135
2022 Q1	$48K	Buy	+8,355	New	+$61.1K	﹤0.01%	1342
2021 Q4	–	Sell	-6,787	Closed	-$73K	–	2099
2021 Q3	$73K	Buy	6,787 +4,797	+241%	+$58.4K	﹤0.01%	1432
2021 Q2	$31K	Buy	+1,990	New	+$31.7K	﹤0.01%	1563
2020 Q2	–	Sell	-177	Closed	-$2K	–	1261
2020 Q1	$2K	Buy	+177	New	+$3.33K	﹤0.01%	849
2018 Q4	–	Sell	-47	Closed	-$1K	–	1025
2018 Q3	$1K	Sell	47 -1,977	-98%	-$73.6K	﹤0.01%	819
2018 Q2	$79K	Buy	+2,024	New	+$64.4K	0.03%	353

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Point72 Hong Kong's HRTX Position: Q4 2022 in Review

Point72 Hong Kong sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 25,518 shares — an estimated $108K sold.

Point72 Hong Kong first reported a position in HRTX in Q2 2018 and held it in 7 quarters. The position peaked at $108K in Q3 2022. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Point72 Hong Kong reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 25,518 Heron Therapeutics shares in Q4 2022, an estimated $108K.
Point72 Hong Kong first reported a position in Heron Therapeutics in Q2 2018 and held it in 7 quarters.
Point72 Hong Kong's Heron Therapeutics position peaked at $108K in Q3 2022.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.